Securing patents for new dosages of pharmaceutical products is now an established practice before the European Patent Office. However, the Supreme Court’s decision on this topic last year in Actavis v ICOS has caused some to question whether such patents can ever be maintained in the UK Courts. In this webinar, we will consider the law surrounding dosage patents at the EPO and in the UK and the strategic questions which are raised by the Actavis v ICOS decision. We will also look at how this issue is dealt with in other jurisdictions.
Topics will include:
Background to the law on dosage patents at the EPO and in the UK
Summary of the Actavis v ICOS decision of the Supreme Court
Discussion of how to manage the difference in approach around Europe
Review of the global position on dosage patents
This is a technical webinar aimed at:
In-house IP practitioners working in the drug development field
Attorneys involved in drafting, prosecuting and advising on patent claims for dosages which could be pursued in Europe
Practitioners having an interest in dosage patents and pharmaceutical inventions
Can't make this time? Sign up anyway and watch on-demand at a time convenient to you.